Jiangsu Hengrui Medicine

    Hengrui, which made $2.5 billion in sales last year, invests twice as much as any other pharma in R&D, and its investments are paying off: It’s China’s largest pharmaceutical company and a leader in innovation. China’s plan to bulk-purchase generic drugs in 2020 will drive down industry prices, but analysts say only 1% to 2% of Jiangsu’s revenue will be impacted, while competitors in its peer group will be more exposed.

    Subscribe to Fortune's Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.

    Company Information

    Overall Score21
    SectorHealth Care
    CEOSun Piaoyang
    HQ LocationLianyungang, China
    Revenues ($M) (Past 12 Months)$2,884
    Profits ($M) (Past 12 Months)$669
    Market Value as of Oct. 9, 2019 ($M)$48,796